Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.
Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported.
Internal Medicine Department, Grenoble University Hospital, Grenoble, France. cfaisant@chu-grenoble.fr.|Grenoble Alps University, Grenoble, France. cfaisant@chu-grenoble.fr.
Charles
C
Faisant
Dermatology Department, Montpellier University Hospital, Montpellier, France.
Aurélie
A
Du Thanh
Internal Medicine Department, Grenoble University Hospital, Grenoble, France.|Grenoble Alps University, Grenoble, France.
Catherine
C
Mansard
Internal Medicine Department, Grenoble University Hospital, Grenoble, France.|Grenoble Alps University, Grenoble, France.|French National Reference Centre for Angioedema (CREAK), Grenoble, France.
Alban
A
Deroux
Internal Medicine Department, Grenoble University Hospital, Grenoble, France.|French National Reference Centre for Angioedema (CREAK), Grenoble, France.
Isabelle
I
Boccon-Gibod
Internal Medicine Department, Grenoble University Hospital, Grenoble, France.|Grenoble Alps University, Grenoble, France.|French National Reference Centre for Angioedema (CREAK), Grenoble, France.|Inserm-UJF-CEA-CNRS unit 1036, IRTSV, CEA Grenoble, Grenoble, France.
Laurence
L
Bouillet
D000328:Adult; D000369:Aged, 80 and over; D000799:Angioedema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers; D018450:Disease Progression; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D063189:Symptom Assessment; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D015415:Biomarkers; D006634:Histamine H1 Antagonists; D000069444:Omalizumab; D007073:Immunoglobulin E
Idiopathic angioedema; non-histaminergic angioedema; omalizumab